1. Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
- Author
-
Yi Zheng, Ziliang Chen, Wenhua Song, Yu Xu, Zhiqiang Zhao, Yihong Sun, Yuanyuan Wang, Xuhong Geng, Jun Zhao, Xiaowei Zhang, Yanmin Xu, Jeffrey Shi Kai Chan, Gary Tse, Guangping Li, Lili Hong, and Tong Liu
- Subjects
cardiac troponin‐I ,cardiovascular adverse events ,creatine kinase isoenzyme‐MB ,immune checkpoint inhibitor ,myocarditis ,neutrophil to lymphocyte ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Over the past decade, immune checkpoint inhibitors (ICIs) have significantly transformed cancer treatment. However, ICIs inevitably may cause a spectrum of immune‐related adverse events, among which cardiovascular toxicity, particularly myocarditis, while infrequent, has garnered increasing attention due to its high fatality rate. Methods We conducted a multicenter retrospective study to characterize ICI‐associated cardiovascular adverse events. Logistic regression was performed to explore the risk factors for the development of myocarditis and severe myocarditis. Receiver operating characteristic curves were conducted to assess the diagnostic abilities of cardiac biomarkers to distinguish different cardiovascular toxicities, and the performance and calibration were evaluated using Hosmer–Lemeshow test. Results Forty‐four patients were identified, including thirty‐five myocarditis, five heart failure, three arrhythmias, and one myocardial infarction. Compared with other patients, myocarditis patients had higher cardiac troponin‐I (cTnI) levels (p
- Published
- 2024
- Full Text
- View/download PDF